Home
    • Plans Blog Contact
    Tiziana Life Sciences Ltd logo

    Tiziana Life Sciences Ltd

    TLSA
    Last price US$0.892
    Market cap US$92.0m
    12M price change -48.71%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Tiziana Life Sciences Ltd Overview

    Industry: Biotechnology

    Sector: Healthcare

    Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom. Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Cr Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Tiziana Life Sciences Ltd into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Jul 22, 2026

    Quarterly result summary

    Exhibit 99.1 Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman BOSTON, MA, July 22, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapi...

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jul 22, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jun 25, 2026 Earnings release TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED JUNE 25, 2026 Jun 25, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jun 15, 2026 Earnings release TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED JUNE 15, 2026 Jun 15, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER May 28, 2026 Earnings material TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED MAY 28, 2026 May 28, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER May 21, 2026 Earnings release TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED MAY 21, 2026 May 21, 2026 Earnings release TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED MAY 19, 2026 May 19, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER May 19, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 2.00/5
    Tiziana Life Sciences Ltd earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.96/5
    Tiziana Life Sciences Ltd exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Tiziana Life... TLSA US$92.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Tiziana Life Sciences Ltd olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Tiziana Life... TLSA US$92.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 3.20/5
    Tiziana Life Sciences Ltd attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Tiziana Life... TLSA US$92.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Tiziana Life Sciences Ltd logo

    Tiziana Life Sciences Ltd

    US$0.892

    US$92.0m

    -16.59%

    -48.71%